{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:02:30Z","timestamp":1793109750336,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T00:00:00Z","timestamp":1666656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T00:00:00Z","timestamp":1666656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-022-03395-y","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T09:02:56Z","timestamp":1666688576000},"page":"1025-1032","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Immune checkpoints inhibitors and its link to acute kidney injury and renal prognosis"],"prefix":"10.1007","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1297-0675","authenticated-orcid":false,"given":"Mehmet","family":"Kanbay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah Burak","family":"Yildiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrie","family":"Siriopol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sezan","family":"Vehbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuri Baris","family":"Hasbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yavuz E.","family":"Kesgin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melisa","family":"Celayir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatih","family":"Selcukbiricik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Covic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Perazella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,25]]},"reference":[{"issue":"7","key":"3395_CR1","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.2215\/CJN.02050309","volume":"4","author":"MA Perazella","year":"2009","unstructured":"Perazella MA (2009) Renal vulnerability to drug toxicity. Clin J Am Soc Nephrol 4(7):1275\u20131283","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"3395_CR2","first-page":"1528","volume":"23","author":"T Dagel","year":"2018","unstructured":"Dagel T, Misirlioglu S, Tanju S, Afsar B, Selcukbiricik F, Erus S et al (2018) Hyperthermic intraperitonal chemotherapy is an independent risk factor for development of acute kidney injury. J BUON 23(5):1528\u20131533","journal-title":"J BUON"},{"issue":"1","key":"3395_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/07853890510007205","volume":"37","author":"NH Lameire","year":"2005","unstructured":"Lameire NH, Flombaum CD, Moreau D, Ronco C (2005) Acute renal failure in cancer patients. Ann Med 37(1):13\u201325","journal-title":"Ann Med"},{"issue":"9","key":"3395_CR4","doi-asserted-by":"publisher","first-page":"4618","DOI":"10.3390\/ijms22094618","volume":"22","author":"J Jagie\u0142a","year":"2021","unstructured":"Jagie\u0142a J, Bartnicki P, Rysz J (2021) Nephrotoxicity as a complication of chemotherapy and immunotherapy in the treatment of colorectal cancer, melanoma and non-small cell lung cancer. Int J Mol Sci 22(9):4618","journal-title":"Int J Mol Sci"},{"issue":"22","key":"3395_CR5","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F et al (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378(22):2078\u20132092","journal-title":"N Engl J Med"},{"issue":"11","key":"3395_CR6","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ (2020) A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol 20(11):651\u2013668","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"3395_CR7","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/annonc\/mdz011","volume":"30","author":"O Hamid","year":"2019","unstructured":"Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R et al (2019) Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol 30(4):582\u2013588","journal-title":"Ann Oncol"},{"issue":"2","key":"3395_CR8","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/jcpt.13071","volume":"45","author":"F Selcukbiricik","year":"2020","unstructured":"Selcukbiricik F, Ozdogan E, Dagel T, Tanju S, Erus S, Ertuglu LA et al (2020) Elevation in serum uric acid levels predicts favourable response to erlotinib treatment in patients with metastatic non-small-cell lung cancer. J Clin Pharm Ther 45(2):303\u2013308","journal-title":"J Clin Pharm Ther"},{"key":"3395_CR9","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.3389\/fimmu.2018.02374","volume":"9","author":"E Gianchecchi","year":"2018","unstructured":"Gianchecchi E, Fierabracci A (2018) Inhibitory receptors and pathways of lymphocytes: the role of PD-1 in Treg development and their involvement in autoimmunity onset and cancer progression. Front Immunol 9:2374","journal-title":"Front Immunol"},{"issue":"6","key":"3395_CR10","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","volume":"170","author":"SC Wei","year":"2017","unstructured":"Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAS, Andrews MC et al (2017) Distinct cellular mechanisms underlie Anti-CTLA-4 and Anti-PD-1 checkpoint blockade. Cell 170(6):1120\u201333.e17","journal-title":"Cell"},{"issue":"4","key":"3395_CR11","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nrd.2015.35","volume":"15","author":"A Hoos","year":"2016","unstructured":"Hoos A (2016) Development of immuno-oncology drugs\u2013from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov 15(4):235\u2013247","journal-title":"Nat Rev Drug Discov"},{"issue":"23","key":"3395_CR12","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O\u2019Day S, Weber JS, Hamid O, Lebb\u00e9 C et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15(23):7412\u20137420","journal-title":"Clin Cancer Res"},{"key":"3395_CR13","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/j.1600-065X.2008.00662.x","volume":"224","author":"BT Fife","year":"2008","unstructured":"Fife BT, Bluestone JA (2008) Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 224:166\u2013182","journal-title":"Immunol Rev"},{"issue":"12","key":"3395_CR14","volume":"12","author":"M Tinawi","year":"2020","unstructured":"Tinawi M, Bastani B (2020) Nephrotoxicity of immune checkpoint inhibitors: acute kidney injury and beyond. Cureus 12(12):e12204","journal-title":"Cureus"},{"issue":"6332","key":"3395_CR15","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1126\/science.aaf1292","volume":"355","author":"E Hui","year":"2017","unstructured":"Hui E, Cheung J, Zhu J, Su X, Taylor MJ, Wallweber HA et al (2017) T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science 355(6332):1428\u20131433","journal-title":"Science"},{"issue":"2","key":"3395_CR16","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378(2):158\u2013168","journal-title":"N Engl J Med"},{"issue":"3","key":"3395_CR17","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","volume":"90","author":"FB Cortazar","year":"2016","unstructured":"Cortazar FB, Marrone KA, Troxell ML, Ralto KM, Hoenig MP, Brahmer JR et al (2016) Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int 90(3):638\u2013647","journal-title":"Kidney Int"},{"issue":"2","key":"3395_CR18","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000455014","volume":"45","author":"R Wanchoo","year":"2017","unstructured":"Wanchoo R, Karam S, Uppal NN, Barta VS, Deray G, Devoe C et al (2017) Adverse renal effects of immune checkpoint inhibitors: a narrative review. Am J Nephrol 45(2):160\u2013169","journal-title":"Am J Nephrol"},{"key":"3395_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfab034","author":"C Garc\u00eda-Carro","year":"2021","unstructured":"Garc\u00eda-Carro C, Bolufer M, Bury R, Cata\u00f1eda Z, Mu\u00f1oz E, Felip E et al (2021) Acute kidney injury as a risk factor for mortality in oncological patients receiving check-point inhibitors. Nephrol Dial Transplant. https:\/\/doi.org\/10.1093\/ndt\/gfab034","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"3395_CR20","doi-asserted-by":"publisher","first-page":"e000467","DOI":"10.1136\/jitc-2019-000467","volume":"8","author":"A Meraz-Mu\u00f1oz","year":"2020","unstructured":"Meraz-Mu\u00f1oz A, Amir E, Ng P, Avila-Casado C, Ragobar C, Chan C et al (2020) Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes. J Immunother Cancer 8(1):e000467","journal-title":"J Immunother Cancer"},{"issue":"2","key":"3395_CR21","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1681\/ASN.2019070676","volume":"31","author":"FB Cortazar","year":"2020","unstructured":"Cortazar FB, Kibbelaar ZA, Glezerman IG, Abudayyeh A, Mamlouk O, Motwani SS et al (2020) Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study. J Am Soc Nephrol 31(2):435\u2013446","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"3395_CR22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/ckj\/sfy100","volume":"12","author":"H Izzedine","year":"2019","unstructured":"Izzedine H, Mathian A, Champiat S, Picard C, Mateus C, Routier E et al (2019) Renal toxicities associated with pembrolizumab. Clin Kidney J 12(1):81\u201388","journal-title":"Clin Kidney J"},{"issue":"9","key":"3395_CR23","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604\u2013612","journal-title":"Ann Intern Med"},{"issue":"4","key":"3395_CR24","doi-asserted-by":"publisher","first-page":"c179","DOI":"10.1159\/000339789","volume":"120","author":"A Khwaja","year":"2012","unstructured":"Khwaja A (2012) KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 120(4):c179\u2013c184","journal-title":"Nephron Clin Pract"},{"key":"3395_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfac194","author":"M Kanbay","year":"2022","unstructured":"Kanbay M, Copur S, Siriopol D, Yildiz AB, Berkkan M, Popa R et al (2022) The association of acute kidney injury on outcomes in cancer patients receiving immune checkpoint inhibitor therapy: a systematic review and meta-analysis. Clin Kidney J. https:\/\/doi.org\/10.1093\/ckj\/sfac194","journal-title":"Clin Kidney J"},{"issue":"11","key":"3395_CR26","doi-asserted-by":"publisher","first-page":"6109","DOI":"10.3390\/ijms22116109","volume":"22","author":"E Kwiatkowska","year":"2021","unstructured":"Kwiatkowska E, Doma\u0144ski L, Dziedziejko V, Kajdy A, Stefa\u0144ska K, Kwiatkowski S (2021) The mechanism of drug nephrotoxicity and the methods for preventing kidney damage. Int J Mol Sci 22(11):6109","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3395_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1681\/ASN.2015040405","volume":"27","author":"SR Mulay","year":"2016","unstructured":"Mulay SR, Linkermann A, Anders HJ (2016) Necroinflammation in kidney disease. J Am Soc Nephrol 27(1):27\u201339","journal-title":"J Am Soc Nephrol"},{"issue":"29","key":"3395_CR28","doi-asserted-by":"publisher","first-page":"12024","DOI":"10.1073\/pnas.1305538110","volume":"110","author":"A Linkermann","year":"2013","unstructured":"Linkermann A, Brasen JH, Darding M, Jin MK, Sanz AB, Heller JO et al (2013) Two independent pathways of regulated necrosis mediate ischemia-reperfusion injury. Proc Natl Acad Sci USA 110(29):12024\u201312029","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"3395_CR29","doi-asserted-by":"publisher","first-page":"18600","DOI":"10.1038\/s41598-019-55079-w","volume":"9","author":"B Popper","year":"2019","unstructured":"Popper B, Rammer MT, Gasparitsch M, Singer T, Keller U, Doring Y et al (2019) Neonatal obstructive nephropathy induces necroptosis and necroinflammation. Sci Rep 9(1):18600","journal-title":"Sci Rep"},{"key":"3395_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.574271","volume":"11","author":"R Franzin","year":"2020","unstructured":"Franzin R, Netti GS, Spadaccino F, Porta C, Gesualdo L, Stallone G et al (2020) The use of immune checkpoint inhibitors in oncology and the occurrence of AKI: where do we stand? Front Immunol 11:574271","journal-title":"Front Immunol"},{"issue":"2","key":"3395_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001198","volume":"8","author":"V Patel","year":"2020","unstructured":"Patel V, Elias R, Formella J, Schwartzman W, Christie A, Cai Q et al (2020) Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma. J Immunother Cancer 8(2):e001198","journal-title":"J Immunother Cancer"},{"key":"3395_CR32","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.abc4764","author":"G Sriram","year":"2021","unstructured":"Sriram G, Milling LE, Chen JK, Kong YW, Joughin BA, Abraham W et al (2021) The injury response to DNA damage in live tumor cells promotes antitumor immunity. Sci Signal. https:\/\/doi.org\/10.1126\/scisignal.abc4764","journal-title":"Sci Signal"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-022-03395-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-022-03395-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-022-03395-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T13:14:11Z","timestamp":1679404451000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-022-03395-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,25]]},"references-count":32,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["3395"],"URL":"https:\/\/doi.org\/10.1007\/s11255-022-03395-y","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,25]]},"assertion":[{"value":"26 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Review Board of Koc University School of Medicine.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}